A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response

Table 1 General scheme of the trial

	Run-in period	Study period	Observation period
SBRT		Three fractions of 8 Gy every other day
Anti-PD-1 treatment	First cycle		Second cycle	Continuation

ISSN: 1479-5876